ANTIBODY-MEDIATED REJECTION
Clinical trials for ANTIBODY-MEDIATED REJECTION explained in plain language.
Never miss a new study
Get alerted when new ANTIBODY-MEDIATED REJECTION trials appear
Sign up with your email to follow new studies for ANTIBODY-MEDIATED REJECTION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug trial aims to save transplanted kidneys from immune attack
Disease control Recruiting nowThis study is testing an experimental drug called felzartamab in people who have received a kidney transplant and whose immune system is attacking the new kidney. About 120 participants will be randomly assigned to receive either felzartamab or a placebo (an inactive substance) t…
Matched conditions: ANTIBODY-MEDIATED REJECTION
Phase: PHASE3 • Sponsor: Biogen • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
New shot aims to save transplanted kidneys from rejection
Disease control Recruiting nowThis study is testing whether a new injectable drug called efgartigimod can help control antibody-mediated rejection in people who have received a kidney transplant. About 30 participants will receive either the drug or a placebo via a prefilled syringe for 48 weeks while continu…
Matched conditions: ANTIBODY-MEDIATED REJECTION
Phase: PHASE2 • Sponsor: argenx • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
New drug trial aims to stop kidney transplant rejection
Disease control Recruiting nowThis study is testing whether an experimental drug called ALXN2030 can help control antibody-mediated rejection in adults who have received kidney transplants. About 45 participants will receive either one of two doses of ALXN2030 or a placebo for 52 weeks, along with their stand…
Matched conditions: ANTIBODY-MEDIATED REJECTION
Phase: PHASE2 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Mar 16, 2026 15:25 UTC